CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. / (Record no. 1198)

MARC details
000 -LEADER
fixed length control field 03471naa a22005537i 4500
001 - CONTROL NUMBER
control field UMUN-OA-20261005-MLS-056
003 - CONTROL NUMBER IDENTIFIER
control field local
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20261005174905.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr||||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 261005s2022 xx o u000 0 eng d
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/fimmu.2022.927153
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (local)EuropePMC:PMC9226391
040 ## - CATALOGING SOURCE
Original cataloging agency local
Language of cataloging eng
Transcribing agency local
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Xiaomin Zhang
Relator term author.
245 10 - TITLE STATEMENT
Title CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. /
Statement of responsibility, etc. Xiaomin Zhang; Lingling Zhu; Hui Zhang [and others].
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture [Place of publication not identified] :
Name of producer, publisher, distributor, manufacturer Frontiers Media SA,
Date of production, publication, distribution, manufacture, or copyright notice 2022.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (1 article).
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
500 ## - GENERAL NOTE
General note Publication type: Review article.
500 ## - GENERAL NOTE
General note Linked open-access copy: published version.
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open access; no subscription required for the linked open-access version.
Standardized terminology for access restriction Unrestricted online access
Source of term star
520 3# - SUMMARY, ETC.
Summary, etc. Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC9226391">https://europepmc.org/articles/PMC9226391</a>
546 ## - LANGUAGE NOTE
Language note In English.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 ## - LOCAL NOTE (RLIN)
Local note Course allocation: B. Sc. Medical Laboratory Science.
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hematological malignancies
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Combinatorial Therapy
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antigen Escape
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunosuppressive Tumor Microenvironment
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Car-t Cell
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Car-t Related Toxicities
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term B. Sc. Medical Laboratory Science
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term UMUN open access collection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hematology
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Review articles.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Lingling Zhu
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Hui Zhang
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Shanshan Chen
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Yang Xiao
Relator term author.
773 0# - HOST ITEM ENTRY
Title Frontiers in immunology
Related parts Vol. 13, (2022), pages/article 927153
International Standard Serial Number 1664-3224
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC9226391">https://europepmc.org/articles/PMC9226391</a>
Link text Read open-access publication
Public note Open access.
Access status 0
884 ## - DESCRIPTION CONVERSION INFORMATION
Conversion process Course selection and automated MARC21 enrichment from Europe PMC metadata.
Conversion date 20261005
Identifier of source metadata https://europepmc.org/articles/PMC9226391
Conversion agency local
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC No

No items available.